Mumbai, 3rd July 2007: Indoco Remedies Ltd today announced that its solid dosage facility at Goa, Plant I has received approval from Brazilian food and drug agency, Anvisa, marking the beginning of company's foray into one of the largest pharmaceutical market in the world. This approval paves way for contract manufacturing opportunities for Indoco in Brazil. |
Ms. Aditi Kare Panandikar, Director Business development said," As a part of companies growth strategy & to move up the value chain, Indoco Remedies intends to enter newer, semi-regulated and regulated markets worldwide after getting approvals from the respective regulatory authorities". |
In addition, Indoco Remedies is working towards obtaining MCC approvals, for their Solid dosage as well as Sterile Plants. Out of Company's two manufacturing facilities at Goa, Plant I is approved by MHRA-UK, for Tablets, Cream & Capsules and by Darmstadt Germany for Solid Dosages. Plant II is a state-of-the-art sterile facility for Ophthalmics and Injectables approved by USFDA. |
About Indoco Remedies Ltd. |
Indoco Remedies is a fast growing Indian Company involved in Research & Development, Manufacturing, Marketing and Distribution of Pharmaceutical products and services in the Domestic and International Market. Indoco has a very strong domestic presence and has strategically aligned itself for a giant leap to be a global player. The company has presence in the Anti-infectives, Anti-spasmodic, Anti-cold, oral hygiene, ophthalmic and lifestyle product segments. The company's brands - Febrex Plus, Cyclopam and Vepan are ranked among the top 250 brands as per ORG rankings. |